Fulvestrant in metastatic breast cancer.

被引：0
|
作者：
Steger, GG [1 ]
Bartsch, R [1 ]
Wenzel, C [1 ]
Pluschnig, U [1 ]
Hussian, D [1 ]
Mader, RM [1 ]
Zielinski, CC [1 ]
机构：
[1] Univ Vienna, Vienna, Austria
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2003年 / 82卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
437
引用
收藏
页码：S104 / S104
页数：1
相关论文
共 50 条
  • [1] Development of orally bioavailable prodrugs of fulvestrant for the treatment of metastatic/advanced breast cancer.
    Purohit, Parva
    Brahmkshatriya, Pathik
    Goswami, Vishalgiri
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Anastrozole and Fulvestrant in Metastatic Breast Cancer
    Ramaekers, Ryan
    Jabbour, Melhem
    Copur, M. Sitki
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (17): : 1662 - 1663
  • [3] Predicting hyperglycemia among patients receiving alpelisib plus fulvestrant for metastatic breast cancer.
    Ge, Xuan
    Behrendt, Carolyn E.
    Yost, Susan Elaine
    Patel, Niki
    Samoa, Raynald
    Stewart, Daphne B.
    Sedrak, Mina S.
    Lavasani, Sayeh Moazami
    Waisman, James Ross
    Yuan, Yuan
    Mortimer, Joanne E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] An evaluation of fulvestrant for the treatment of metastatic breast cancer
    Soleja, Mohsin
    Raj, Ganesh V.
    Unni, Nisha
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (15) : 1819 - 1829
  • [5] Fulvestrant plus anastrozole for metastatic breast cancer
    Burki, Talha Khan
    [J]. LANCET ONCOLOGY, 2019, 20 (05): : E247 - E247
  • [6] Fulvestrant plus capivasertib for metastatic breast cancer
    Dekker, Tim Johannes Adrianus
    [J]. LANCET ONCOLOGY, 2020, 21 (05): : E232 - E232
  • [7] Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer
    Mehta, Rita S.
    Barlow, William E.
    Albain, Kathy S.
    Vandenberg, Ted A.
    Dakhil, Shaker R.
    Tirumali, Nagendra R.
    Lew, Danika L.
    Hayes, Daniel F.
    Gralow, Julie R.
    Livingston, Robert B.
    Hortobagyi, Gabriel N.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (05): : 435 - 444
  • [8] Fulvestrant plus capivasertib for metastatic breast cancer Reply
    Jones, Robert H.
    Casbard, Angela
    Carucci, Margherita
    Foxley, Andrew
    Howell, Sacha J.
    [J]. LANCET ONCOLOGY, 2020, 21 (05): : E234 - E234
  • [9] Residual estrogen receptor availability during fulvestrant 500 mg therapy in patients with metastatic breast cancer.
    van Kruchten, Michel
    De Vries, Elisabeth
    Brown, Myles
    Glaudemans, Andor W. J. M.
    van Lanschot, Meta C.
    Kema, Ido P.
    Van Faassen, Martijn
    Schroder, Carolien P.
    De Vries, Erik F. J.
    Hospers, Geke
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] Clinical Use of Fulvestrant in Patients with Metastatic Breast Cancer
    Foggi, P.
    Corsetti, S.
    De Luca, C.
    Cauchi, C.
    Viola, G.
    Abbate, M. I.
    Conti, F.
    Carpano, S.
    Lopez, M.
    [J]. ONCOLOGY, 2009, 77 : 145 - 145
12345